<DOC>
	<DOC>NCT00038103</DOC>
	<brief_summary>This is an open-label, multicenter, randomized (1:1 randomization ratio) study of either exemestane or exemestane plus celecoxib in postmenopausal women with ABC having progressed on tamoxifen.</brief_summary>
	<brief_title>Open-Label Study Of Exemestane With Or Without Celecoxib In Postmenopausal Women With ABC Having Progressed On Tamoxifen</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>Postmenopausal female patient with histologically or cytologically confirmed breast cancer having progressed on Tamoxifen. Advanced disease: patients with advanced breast carcinoma with disease progression who had progressed/relapsed following &gt; 8 weeks of treatment with Tamoxifen for advanced disease; or progressed during adjuvant Tamoxifen for at least 6 or 12 months depending on receptor status; or progressed within 12 months from completion of adjuvant treatment with Tamoxifen. at least one measurable lesion More than one previous chemotherapy and/or more than one hormonotherapy for advanced disease. Previous hormonotherapy for advanced disease other than Tamoxifen. Myocardial infarction within previous 6 mo</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
</DOC>